Voyageur Achieves Milestone with Rain Cage Royalty Agreement for Sustainable Carbon Drug Development

Biotech & MedTech, Critical Minerals & Rare Earths

March 13, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Corporation”), announces a significant advancement in its partnership with Rain Cage Carbon Inc. (“Rain Cage”). This milestone signifies the execution of a royalty agreement that solidifies the exclusive development and license agreement between the parties and it further reinforces Voyageur’s commitment to pioneering sustainable carbon drug development.

Brent Willis, CEO of Voyageur states, “Voyageur is pioneering the development of the world’s first carbon-neutral pharmaceutical company. Our groundbreaking carbon drug program may revolutionize the industry, by harnessing captured CO2 as its primary ingredient. This innovative approach not only aligns with sustainable practices but also positions Voyageur as a trailblazer in the radiology drug market through seamless vertical integration. Our Rain Cage partnership is shaping the future of environmentally conscious and cutting-edge pharmaceutical solutions.”

Driving Innovation in Healthcare Imaging

Voyageur and Rain Cage have solidified their strategic alliance and are poised to redefine healthcare imaging technologies. The execution of the royalty agreement underscores their shared dedication to leveraging Rain Cage’s pioneering EDEN™ carbon capture technology for the creation of innovative nanocarbon/fullerene-based imaging drugs.

Building an Eco-Friendly Drug Pipeline

In alignment with its sustainable goals, Voyageur is forging ahead with the establishment of an eco-friendly drug pipeline. This pipeline includes barium sulfate contrast media, iodinated contrast media, and carbon contrast media products, forming an integral part of Voyageur’s Earth to Bottle strategic business plan.

Pioneering MRI Drug Development

With a focus on innovation, Voyageur is spearheading the development of a new MRI drug utilising the V@C60 molecule (  This breakthrough holds promise for revolutionizing MRI imaging as well as facilitating targeted drug delivery of contrast agents to specific areas of the body.

Sustainable Carbon Production for Future Growth

Building upon Rain Cage’s breakthrough in carbon production from captured CO2, Voyageur is poised for sustainable growth ( The preparation of a carbon production Revenue Sharing Agreement is underway to exploit carbon captured and leverage the cash flow generated by carbon production technology at Voyageur’s future pharmaceutical manufacturing facility. Voyageur is evaluating several existing pharmaceutical facilities, to enable the vertical integration of its pharmaceutical projects and align with its vision of integrating sustainability into pharmaceutical production.

Leading the Way in Pharmaceutical Sustainability

Voyageur’s partnership with Rain Cage underscores its leadership in sustainable pharmaceutical development. By executing the royalty agreement and advancing eco-friendly drug development, Voyageur is contributing to a healthier future and a greener planet.

About Voyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under the symbol VM on the TSXV, is in development of barium and iodine Active Pharmaceutical Ingredients (API) and high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium and iodine contrast market, Voyageur aims to become a key player by producing its own barium, iodine, and fullerene minerals.

Voyageur’s business plan is set to generate immediate cash flow by partnering with established third-party GMP pharmaceutical manufacturers in Canada, ensuring the validation of its products by regulatory agencies worldwide. As Voyageur solidifies its presence in the market, it will transition into a high-margin domestic manufacturer of radiology drugs, further expanding its revenue streams.

Voyageur is committed to sustainability and environmental stewardship. Voyageur envisions a future where carbon neutrality is the norm, and to achieve this, it is building state-of-the-art carbon-neutral infrastructure. By investing in carbon neutral energy sources and sustainable manufacturing practices, Voyageur aims to become 100% self-sufficient across all of its manufacturing activities. Voyageur’s unwavering commitment to the environment sets it apart as a pioneer in the industry.

At the core of its operations, Voyageur owns a 100% interest in the Frances Creek barium sulphate (barite) project. This project boasts exceptional grade minerals suitable for the pharmaceutical marketplace.

Voyageur’s ambitious vision is to become the first vertically integrated, carbon-neutral company in the radiology contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to the final production, Voyageur ensures unmatched quality and cost efficiency. With its  revolutionary approach, it embodies the motto of “From the Earth to the Bottle,” highlighting Voyageur’s commitment to responsible sourcing and manufacturing practices.

About Rain Cage Carbon Inc.

Rain Cage is a pioneering private Canadian company dedicated to decarbonizing industries by capturing CO2 and other emissions and transforming them into engineered carbon. Through its proprietary technology, EDEN™, it offers companies a groundbreaking solution to combat carbon pollution. Rain Cage’s unique approach not only helps mitigate emissions but also harnesses contaminating energy and converts it into a recyclable technology with countless applications.

For Further Information:

Brent Willis, CEO,Albert Deslauriers, CFO,
[email protected][email protected]
[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding “Forward-Looking” Information

This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to: the success of utilizing Rain Cage’s EDENTM carbon capture technology to create innovative nanocarbon/fullerene-based imaging drugs and the success of the Corporation’s profitability manufacturing and distributing those drugs; all required regulatory approvals being obtained for the manufacture and sale of the nanocarbon/fullerene-based imaging drugs; the market for fullerene based contrast agents; the EDENTM technology being carbon neutral; and availability of financing. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company’s disclosure documents on the SEDAR+ website at Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.

Voyageur Pharmaceuticals Ltd.

Voyageur Pharmaceuticals Ltd. (TSXV: VM), a Canadian public company trading under the symbol VM on the TSX Venture Exchange, is in development of barium, iodine and carbon Active…

Leave a Reply

Your email address will not be published. Required fields are marked *